Details for Patent: 11,090,261
✉ Email this page to a colleague
Which drugs does patent 11,090,261 protect, and when does it expire?
Patent 11,090,261 protects RYZUMVI and is included in one NDA.
This patent has ten patent family members in eight countries.
Drugs Protected by US Patent 11,090,261
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Famygen Life Sci | RYZUMVI | phentolamine mesylate | SOLUTION;OPHTHALMIC | 217064-001 | Sep 25, 2023 | RX | Yes | Yes | 11,090,261 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,090,261
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2014212274 | ⤷ Subscribe | |||
| Australia | 2018200566 | ⤷ Subscribe | |||
| Canada | 2899339 | ⤷ Subscribe | |||
| Denmark | 2950648 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
